LIMK-1/2 (Ser104) Antikörper
-
- Target
- LIMK-1/2
-
Bindungsspezifität
- Ser104
-
Reaktivität
- Human, Ratte, Maus, Affe
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Unkonjugiert
-
Applikation
- Western Blotting (WB), Immunohistochemistry (IHC), ELISA
- Spezifität
- LIMK-1/2 Polyclonal Antibody detects endogenous levels of LIMK-1/2 protein.
- Produktmerkmale
- Rabbit Polyclonal to LIMK-1/2.
- Aufreinigung
- The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
- Immunogen
- Synthesized peptide derived from human LIMK-1/2 around the non-phosphorylation site of T508/505.
- Isotyp
- IgG
-
anti-LIMK-1/2 (pThr505), (pThr508) antibody
Reaktivität: Human, Ratte, Maus WB, IHC, ELISA, IF, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-LIMK-1/2 (C-Term), (pSer505), (pSer508) antibodyReaktivität: Human, Ratte, Huhn, Rind (Kuh) WB, IHC, IF, IC Wirt: Kaninchen Polyclonal unconjugated
anti-LIMK-1/2 (pThr505), (pThr508) antibodyReaktivität: Human, Ratte, Maus WB, IHC, ELISA Wirt: Kaninchen Polyclonal unconjugated
anti-LIMK-1/2 (AA 481-530) antibodyReaktivität: Human, Ratte, Maus WB, IHC, ELISA Wirt: Kaninchen Polyclonal unconjugated
anti-LIMK-1/2 (C-Term) antibodyReaktivität: Human, Ratte, Maus, Huhn, Rind (Kuh) WB, IP Wirt: Kaninchen Polyclonal unconjugated
anti-LIMK-1/2 (C-Term), (pSer505), (pSer508) antibodyReaktivität: Human, Ratte, Maus, Huhn, Rind (Kuh) WB Wirt: Kaninchen Polyclonal unconjugated
-
- Applikationshinweise
- WB 1:500-1:2000, IHC 1:100-1:300, ELISA 1:40000,
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 mg/mL
- Buffer
- Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handhabung
- Avoid repeated freeze/thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20°C.
-
-
